Shamburg News · 8-K filed Nov 18, 2026, 8:10 AM EST

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Update

RTSN · Retension Pharmaceuticals, Inc.

  • Earnings
  • Financing
  • Materiality: high

Retension Pharmaceuticals reported a net loss of $5.9 million for the third quarter ended September 30, 2026, compared with a net loss of $1.5 million a year earlier, as research and development expenses rose to $5.0 million. Cash and cash equivalents were $9.2 million at September 30, 2026, and the company said its IPO, which closed after quarter-end, added net proceeds of approximately $45.1 million. The upsized IPO of 4,312,500 shares at $12.00 per share generated gross proceeds of $51.75 million in October 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-129354.

Written from the filing by Shamburg Markets. Figures are as reported by the company.